Current stock page

Catalysts

VRTX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

VRTXVertex Pharmaceuticals Incorporated

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$538.60−$4.02 (−0.74%)

Latest quote

  • Momentum
    83
  • Value
    70
  • Quality
    71
  • Risk resilience
    80
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 11, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 77/100

Momentum 83/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 36.33%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 83/100AIQ Edge 10/10 Sector Leader
Beat rate
38%
3 of 8 reported periods
Average surprise
+0.9%
Across covered historical reports
Latest result
-1.2%
Nov 2, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 2, 2026—$4.82$4.76-1.2%$3.42B$3.44B
Aug 3, 2026—$4.74$4.73-0.2%$3.23B$3.33B
May 4, 2026—$4.24$4.47+5.4%$2.99B$2.99B
Feb 12, 2026—$5.11$5.03-1.6%$3.18B$3.19B
Nov 3, 2025—$4.57$4.80+5.0%$3.06B$3.08B
Aug 4, 2025—$4.29$4.52+5.4%$2.91B$2.96B
May 5, 2025—$4.25$4.06-4.5%$2.86B$2.77B
Feb 10, 2025—$4.02$3.98-1.0%$2.78B$2.91B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
26
Buy
5
Hold
2
Sell
12-month analyst target
$620.40
+15.19% versus current price
Based on 33 analyst observations. Targets are estimates, not predictions.
Low target
$570.00
+5.83% vs latest price
Average target
$620.40
+15.19% vs latest price
High target
$665.00
+23.47% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 11, 2027

Next known earnings or reporting date.

EPS estimate$4.20

Current analyst expectation for the upcoming report.

Revenue estimate$3.5B

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score83

Where event reaction would show up first.

AIQ score77/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
33
Average target
$620.40
Target upside
15.19%
Target range
$570.00 - $665.00
90-day revisions
-10

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
2
Negative
0
zacks.com · Nov 11, 2026

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

seekingalpha.com · Nov 6, 2026

Vertex Pharmaceuticals: Costs Now Outgrow Sales, And Price Needs A Second Vertex

Vertex Pharmaceuticals is rated Sell, with fair value estimated at $398.25 versus a $530.76 share price. Read more on VRTX stock here.

gurufocus.com · Oct 21, 2026

Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members with Appointment of Former Boston Scientific CFO Daniel Brennan

Vertex Pharmaceuticals Incorporated (VRTX) announced that Daniel Brennan has been appointed as a new member of its board of directors, effective October 20, 20

finance.yahoo.com · Sep 12, 2026

Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an

Open full news and sentiment

VRTX Catalysts FAQ

What are the next catalysts for VRTX stock?

VRTX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move VRTX stock?

Upcoming events that could move VRTX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could VRTX's next earnings report affect the stock?

VRTX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive VRTX stock higher?

VRTX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt VRTX stock?

VRTX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.